CY1117881T1 - Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων - Google Patents

Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων

Info

Publication number
CY1117881T1
CY1117881T1 CY20161100768T CY161100768T CY1117881T1 CY 1117881 T1 CY1117881 T1 CY 1117881T1 CY 20161100768 T CY20161100768 T CY 20161100768T CY 161100768 T CY161100768 T CY 161100768T CY 1117881 T1 CY1117881 T1 CY 1117881T1
Authority
CY
Cyprus
Prior art keywords
solid pharmaceutical
pharmaceutical compositions
compositions
biopterine
producers
Prior art date
Application number
CY20161100768T
Other languages
English (en)
Inventor
Frank Tegtmeier
Reinhard Schinzel
Peter Scheurer
Original Assignee
Vasopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharm Gmbh filed Critical Vasopharm Gmbh
Publication of CY1117881T1 publication Critical patent/CY1117881T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με στερεές φαρμακευτικές συνθέσεις που περιλαμβάνουν παράγωγα βιοπτερίνης όπως επίσης και με μεθόδους για λήψη αυτών των στερεών φαρμακευτικών συνθέσεων. Οι συνθέσεις περιέχουν το δραστικό συστατικό και φωσφορικά. Μπορούν να ληφθούν με λυοφιλίωση και να ανασυσταθούν για ενδοφλέβια χορήγηση. Η εφεύρεση επίσης σχετίζεται με τις στερεές φαρμακευτικές συνθέσεις της εφεύρεσης για αντιμετώπιση νόσων.
CY20161100768T 2014-03-31 2016-08-04 Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων CY1117881T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14162727.3A EP2926805B1 (en) 2014-03-31 2014-03-31 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

Publications (1)

Publication Number Publication Date
CY1117881T1 true CY1117881T1 (el) 2018-03-07

Family

ID=50389975

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100768T CY1117881T1 (el) 2014-03-31 2016-08-04 Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων

Country Status (29)

Country Link
US (6) US9895372B2 (el)
EP (2) EP2926805B1 (el)
JP (3) JP6552515B2 (el)
KR (1) KR102374500B1 (el)
CN (2) CN113521017A (el)
AU (2) AU2015239736B2 (el)
CA (1) CA2938267C (el)
CL (1) CL2016002463A1 (el)
CY (1) CY1117881T1 (el)
DK (1) DK2926805T3 (el)
ES (1) ES2586945T3 (el)
HK (1) HK1213195A1 (el)
HR (1) HRP20160802T1 (el)
HU (1) HUE030221T2 (el)
IL (1) IL248090B (el)
MX (1) MX2016012784A (el)
MY (1) MY180844A (el)
PE (1) PE20161253A1 (el)
PH (1) PH12016501519B1 (el)
PL (1) PL2926805T3 (el)
PT (1) PT2926805T (el)
RS (1) RS54973B1 (el)
RU (1) RU2694368C2 (el)
SA (1) SA516371933B1 (el)
SG (1) SG11201606151SA (el)
SI (1) SI2926805T1 (el)
SM (1) SMT201600246B (el)
WO (1) WO2015150294A1 (el)
ZA (1) ZA201605271B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54973B1 (sr) 2014-03-31 2016-11-30 Vasopharm Gmbh Čvrste farmaceutske kompozicije koje uključuju derivate biopterina i upotreba takvih kompozicija
JP2016168783A (ja) * 2015-03-13 2016-09-23 株式会社東芝 記録装置、記録方法、及び記録媒体
JP2020532535A (ja) * 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
JP6565103B2 (ja) * 2017-09-06 2019-08-28 株式会社昭和冷凍プラント 香気成分含有水溶液を含む液状製品の製造方法
KR20220070477A (ko) * 2019-09-25 2022-05-31 피티씨 테라퓨틱스 엠피, 인크. 고페닐알라닌혈증 치료 방법
CA3235704A1 (en) 2021-12-03 2023-06-08 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
TW202406555A (zh) 2022-05-06 2024-02-16 德商veriNOS運營有限公司 治療患有與增加的麩胺酸水平相關的疾病狀況或病症的患者的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
EP0906913B1 (de) 1997-10-06 2001-05-23 Ernst Werner Pteridinderivate als NO Synthase-Hemmer
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
AU2004311544A1 (en) * 2003-11-17 2005-07-21 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
DK1757293T3 (da) * 2004-05-11 2012-10-22 Daiichi Sankyo Co Ltd Bh4-responsiv hyperphenylalaninæmi-medikamenter
SE0401826D0 (sv) 2004-07-09 2004-07-09 Trimble Ab Method of preparing a winding for an n-phase motor
MX2007005039A (es) * 2004-11-17 2007-06-19 Biomarin Pharm Inc Formulacion de tableta estable.
EP1669355A1 (en) * 2004-12-02 2006-06-14 Vasopharm Biotech GmbH Aminotetrahydropteridines and processes for manufacture thereof
DK2139485T3 (da) * 2007-04-11 2013-01-21 Biomarin Pharm Inc Fremgangsmåder til admistration af tetrahydrobiopterin, associerede sammensætninger, og fremgangsmåder til måling
CN101658067B (zh) 2007-04-24 2012-06-27 欧司朗股份有限公司 用于点燃和驱动放电灯的电路装置
WO2010017570A2 (de) * 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
CN103458900A (zh) * 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
EP2750664A1 (en) * 2011-08-30 2014-07-09 Fresenius Kabi USA, LLC Levothyroxine formulations
RS54973B1 (sr) * 2014-03-31 2016-11-30 Vasopharm Gmbh Čvrste farmaceutske kompozicije koje uključuju derivate biopterina i upotreba takvih kompozicija

Also Published As

Publication number Publication date
KR102374500B1 (ko) 2022-03-15
US11717522B2 (en) 2023-08-08
US20210137927A1 (en) 2021-05-13
BR112016020101A8 (pt) 2021-06-29
CA2938267A1 (en) 2015-10-08
CN106572976A (zh) 2017-04-19
JP6552515B2 (ja) 2019-07-31
US20170296543A1 (en) 2017-10-19
SI2926805T1 (sl) 2016-09-30
WO2015150294A1 (en) 2015-10-08
JP7178731B2 (ja) 2022-11-28
CL2016002463A1 (es) 2017-01-27
US20230355630A1 (en) 2023-11-09
EP3125864A1 (en) 2017-02-08
US20170112836A1 (en) 2017-04-27
CA2938267C (en) 2023-05-09
PH12016501519A1 (en) 2017-02-06
IL248090A0 (en) 2016-11-30
DK2926805T3 (en) 2016-07-25
PE20161253A1 (es) 2016-11-13
EP2926805A1 (en) 2015-10-07
US20180289714A1 (en) 2018-10-11
ES2586945T3 (es) 2016-10-19
MX2016012784A (es) 2017-04-25
SMT201600246B (it) 2016-08-31
RU2016141449A3 (el) 2018-12-14
US10016431B2 (en) 2018-07-10
US9895372B2 (en) 2018-02-20
HRP20160802T1 (hr) 2016-08-12
EP2926805B1 (en) 2016-05-18
AU2015239736B2 (en) 2020-03-26
PL2926805T3 (pl) 2016-12-30
SA516371933B1 (ar) 2019-04-14
ZA201605271B (en) 2017-08-30
US10925877B2 (en) 2021-02-23
PH12016501519B1 (en) 2017-02-06
JP2019194227A (ja) 2019-11-07
JP2017509623A (ja) 2017-04-06
JP6879582B2 (ja) 2021-06-02
BR112016020101A2 (el) 2017-07-15
RU2694368C2 (ru) 2019-07-12
AU2020203880B2 (en) 2022-03-31
IL248090B (en) 2019-10-31
AU2020203880A1 (en) 2020-07-02
MY180844A (en) 2020-12-10
US20200046710A1 (en) 2020-02-13
NZ722455A (en) 2022-03-25
HUE030221T2 (en) 2017-04-28
US10493075B2 (en) 2019-12-03
KR20160138406A (ko) 2016-12-05
AU2015239736A1 (en) 2016-08-11
SG11201606151SA (en) 2016-08-30
US20220031703A9 (en) 2022-02-03
HK1213195A1 (zh) 2016-06-30
PT2926805T (pt) 2016-07-15
JP2021105062A (ja) 2021-07-26
RS54973B1 (sr) 2016-11-30
CN113521017A (zh) 2021-10-22
RU2016141449A (ru) 2018-05-07

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1117881T1 (el) Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA201890817A1 (ru) Кристаллические формы бета-никотинамида мононуклеотида
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
EA201892734A1 (ru) ПРОИЗВОДНЫЕ АЗАБЕНЗИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ pI3K BETA
CY1124076T1 (el) Ημιθειικο αλας του 5,10-μεθυλενο-(6r)-τετραϋδροφυλλικου οξεος
EA201690752A1 (ru) Ингибиторы g12c kras
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
EA201692000A1 (ru) Макроциклические производные пиридина
EA201692003A1 (ru) Макроциклические производные пиримидина
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
CY1123532T1 (el) Αναστολεις του gingipain λυσινης
SV2017005381A (es) Compuestos de imidazopiridazina
EA201790046A1 (ru) Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CY1123185T1 (el) Παραγωγα ινδολιου
CY1121708T1 (el) Ενωσεις ουριας ινδανυλιου που αναστελλουν την ρ38 map kιναση
EA201990046A1 (ru) Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета